The board of directors of HBM Holdings Limited announces that Dr. Mai-Jing Liao has tendered his resignation as an executive Director of the Company with effect from 17 September 2021 due to his personal reasons. The Board announced that Mr. Xiaoxiang Chen has been appointed as an executive Director of the Company with effect from 17 September 2021. Mr. Chen is the chief development officer of the Company. Mr. Chen joined Wyeth in February 1998 as a manager of clinical research and regulatory affairs, subsequently serving as director of clinical research in China from February 2001.